A new future for regenerative medicine
NellOne: The Business
NellOne is an early stage biopharmaceutical company using a talented protein to plot a new future for regenerative medicine. That protein is NELL-1 [Neural EGF- Like-Like molecule], a naturally occurring secreted human protein that triggers multiple processes for tissue growth and maturation during development and after injuries. With dozens of patents in eight countries, NellOne Therapeutics, Inc. is developing therapies with partners across multiple modalities leveraging the healing potential of NELL-1.
As a result, NellOne is the home where servant leadership can thrive and a meaningful difference can be made.
NELL-1: The Talented Protein
The remarkable range of NELL-1’s abilities is enabled by stimulating cells to secrete a mixture of molecules called the extracellular matrix (ECM)
—a “biological glue” which orients cells in the correct 3D structure, and allows them to communicate and coordinate their jobs in a specific tissue or organ. The ECM generated by NELL-1 recapitulates the molecular and cellular environment during fetal development—the naturally regenerative phase of human life and the ONLY time when the human body undergoes true regeneration and scarless healing. NELL-1 is most abundant and active during fetal growth and decreases after birth, maturity and aging.
NELL-1: The Potential
The NELL-1 protein yields remarkable potential in treating tissue damage because it promotes biological pathways that:
by controlling the levels of major pro-inflammatory factors including that of the cytokine storm that can overwhelm the body during the early phase of infection.
Increase cell/tissue survival
under hypoxia which provides tissues time and opportunity to initiate and sustain the repair mechanisms.
Maturing new tissue
to full biological function.
Stem cell recruitment
to injury site for tissue formation and blood vessel formation.